Have you or your loved ones been diagnosed with alzheimer disease?

You may be eligible to participate in a alzheimer disease clinical trial.

Have you or your loved ones been diagnosed with alzheimer disease? You may be eligible to participate in a alzheimer disease clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Alzheimer Disease Clinical Trial in London
NCT02874820 | Early phase 1 | Interventional

Have you or your loved ones been diagnosed with alzheimer disease?

You may be eligible to participate in a alzheimer disease clinical trial.

Have you or your loved ones been diagnosed with alzheimer disease? You may be eligible to participate in a alzheimer disease clinical trial.

Terminated

Male

50 - 80

Years old

This study has recruited 2 Participants

The imdazoline2 binding site (I2BS) is known to reside inside astrocytes. Changes in the numbers of I2BS in post mortem tissue has implicated them in a range of psychiatric conditions such as depression and addiction, along with neurodegenerative disorders such as Alzheimer's disease and Huntington's chorea. Preclinical studies have also demonstrated functional interactions with the opioid system, where I2BS ligands have been shown to affect tolerance to morphine and alleviate some of the morphine withdrawal syndrome in rats. Recently the I2BS and I2BS ligands have been shown to have some interesting analgesic effects in different models of pain. The location of I2BS on astrocytic glial cells and the possibility that they may in some way regulate glial fibrillary acidic protein have led to increased interest into the role of I2BS and I2BS ligands in conditions characterised by marked gliosis. The number of I2BS has been shown to increase in Alzheimer's disease post mortem, and it has also been suggested that I2BS may be a marker for the severity and malignancy of human glioblastomas. The lack of suitable imaging tools for the I2BS has meant that information regarding the number and distribution of I2BS in the brain has come from preclinical species and in vitro post-mortem studies. The recent development of [11C]BU99008 as a suitable PET ligand to quantify I2BS in vivo, enables the direct quantification of I2BS availability and regional distribution in the living human brain. In this study the investigators plan to utilise [11C]BU99008 to quantify the regional brain availability of I2BS in the human brain in vivo using PET.